

PATHOLOGY GRAND ROUNDS



Alessandro Santin, MD

Professor, Clinician-Scholar Track; Department of
Obstetrics, Gynecology & Reproductive Sciences
Division of Gynecologic Oncology, YNHH

“HER2/neu in Biologically Aggressive Endometrial Cancer: A Novel Therapeutic Target”

Thursday, January 16th, 2020

12:30 p.m.

Fitkin Amphitheater – LMP 1094

Host: Pei Hui, MD, PhD



There is no corporate or grant support for this activity. This course will fulfill the licensure requirement set forth by the State of Connecticut.

ACCREDITATION

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE=

Attending physicians, researchers, house staff, fellows, residents, medical students, nurses.

NEEDS ASSESSMENT

The role of genetic analysis in cancer is rapidly expanding and is complex and challenging for pathologists to understand and implement such testing in a meaningful and useful manner. Based on the Cancer Genome Atlas, pragmatic molecular classifiers that identify four prognostically distinct molecular subgroups of endometrial carcinoma have been developed. The evolution of genomic classification in endometrial cancer, how to optimally integrate molecular classification into current standard of care, and therapeutic strategies in this setting will be discussed in this lecture. Specifically, appraisal of recent Phase II clinical trials that have demonstrated the benefits of Her2/neu targeted therapies in the management of recurrent or advanced endometrial carcinoma with specific molecular classifiers will be reviewed.

metrial carcinoma have been developed. The evolution of genomic classification in endometrial cancer, how to optimally integrate molecular classification into current standard of care, and therapeutic strategies in this setting will be discussed in this lecture. Specifically, appraisal of recent Phase II clinical trials that have demonstrated the benefits of Her2/neu targeted therapies in the management of recurrent or advanced endometrial carcinoma with specific molecular classifiers will be reviewed.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

- Discuss the evolution of genomic classification in endometrial cancer;

- Optimally integrate molecular classification into current standard of care;
- Discuss the role of HER2/neu as novel therapeutic target in uterine serous carcinoma.

DESIGNATION STATEMENT

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES

Speaker Name: Alessandro Santin, MD - Merck Pharmaceuticals; PUMA Inc, Pharmaceuticals.

Course Directors: Manju Prasad, MD - NONE
Kurt Schalper, MD, PhD - NONE

Pallavi Gopal, MD, PhD - NONE

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.